MMSI: Merit Medical Systems, Inc. - Summary | Jitta

Merit Medical Systems, Inc.

NASDAQ:MMSI

Price
$55.93
Loss Chance
46.6%
4.77JITTA SCORE
6.38%Under Jitta Line
Jitta Ranking
38 / 936
578 / 4,288
Grow your money with Jitta Ranking. See details.
HISTORICAL JITTA SCORE
Jitta Factors
Growth Opportunity (57)
Recent Business Performance (68)
Financial Strength (73)
Return to Shareholders (1)
Competitive Advantage (43)
Jitta Signs
Revenue and EarningConsistent Growth in the past 3 years
Interest Coverage RatioVery Good
Operating MarginDeclined
Debt LevelHigh Long Term Debt
Recent Business PerformanceEarning decline 29.88% in the last year
CapExVery High
SG&A to SalesIncreasing
Cash Conversion CycleMore than 120 days
Key Stats
Jitta Score
Jitta Line
4.77
6.38%
2.30
338.51%
Health Care Supplies
6.24
257.37%
4.85
629.94%
3.90
53.44%
COMPANY DESCRIPTION
Merit Medical Systems, Inc. manufactures and markets disposable medical devices for interventional, diagnostic, and therapeutic procedures in cardiology, radiology, oncology, critical care, and endoscopy. The company operates through two segments, Cardiovascular and Endoscopy. It provides peripheral intervention products for the diagnosis and treatment of diseases in peripheral vessels and organs; and cardiac intervention products, such as access, angiography, hemostasis, intervention, interventional fluid management, pressure monitoring, and cardiac rhythm management, as well as thermodilution and pulmonary artery catheters and electrophysiology to treat various heart conditions. It also offers cardiovascular and critical care products to treat patients with life-threatening diseases, and protect healthcare providers from exposure to bloodborne pathogens. In addition, it provides interventional oncology and spine products to treat vertebral compression fractures, metastatic spinal tumors, liver cancer, uterine fibroids, benign prostatic hyperplasia, vertebral compression fractures, and arteriovenous malformations and hemostatic embolization, as well as breast cancer localization and guidance products for the treatment of breast cancer. Further, it offers non-vascular stents to treat pulmonary and gastrointestinal diseases; dilation balloons to endoscopically dilate strictures; and kits and accessories for endoscopy and bronchoscopy procedures. Additionally, it provides coated tubes and wires; microelectromechanical system sensor components; ConvertX nephroureteral stent system; and Fibrovein, a detergent-based sclerosant. The company sells its products to hospitals and clinic-based physicians, technicians, and nurses through direct sales force, distributors, original equipment manufacturer partners, or custom procedure tray manufacturers in the United States and internationally. The company was founded in 1987 and is headquartered in South Jordan, Utah.